CStone Pharmaceuticals, a biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, announced today that the new drug application (NDA) for pralsetinib for the treatment of rearranged during transfection (RET) fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) has been accepted in Hong Kong, China. Pralsetinib is…
从这篇文章中可以得到什么：
- 专注于肿瘤免疫创新疗法和精准医疗研发及商业化的生物制药公司基石药业今日宣布获得pralsetinib新药上市申请（NDA），用于治疗局部转染重排（RET）融合阳性的肿瘤晚期或转移性非小细胞肺癌（NSCLC）已在中国香港接受。
- 订阅是免费的。
- eTurboNews 文章仅供订阅者使用。
